Swethajit Biswas
About Swethajit Biswas
Swethajit Biswas serves as a Medicine Development Leader at Adaptimmune, where he has worked since 2019. He specializes in developing real-world evidence packages for cell therapies in rare cancers and has extensive experience in clinical trials and strategic direction for solid cancer therapies.
Work at Adaptimmune
Swethajit Biswas has been serving as the Medicine Development Leader at Adaptimmune since 2019. In this role, he focuses on developing real-world evidence packages, which include non-interventional studies for cell therapy targeting rare cancers. His work is aimed at regulatory agencies and health technology assessments. He provides strategic direction for cell therapies in solid cancers and emphasizes therapeutic landscaping in relation to the current standard of care. Biswas leads the development of an autologous TCR T cell therapy in solid cancers, concentrating on a registration-directed trial.
Previous Experience at GSK
Before joining Adaptimmune, Swethajit Biswas worked at GlaxoSmithKline (GSK) as a Clinical Director from 2014 to 2019. His responsibilities included designing, developing, and executing Phase 1 and 2 trials for T-cell therapies in solid cancers. This role allowed him to gain significant experience in clinical trial management and the advancement of cancer therapies.
Academic Background
Swethajit Biswas studied at the University of Oxford, where he earned a Doctor of Philosophy (PhD) in Oncology and Cancer Biology from 2004 to 2007. Prior to that, he attended The University of Sheffield, achieving an MB, ChB (Honours) First Class degree in Medicine from 1991 to 1996. His academic background provides a solid foundation for his work in medical oncology and clinical development.
Experience at Newcastle University
From 2009 to 2013, Swethajit Biswas served as an Associate Professor in Medical Oncology at Newcastle University. During this period, he contributed to the academic and clinical research environment, focusing on oncology. His role involved mentoring students and conducting research that aligns with his expertise in cancer therapies.
Clinical Trial Design and Development
Swethajit Biswas has extensive experience in clinical trial design and development. He has previously designed and executed a Phase 1/2 platform trial for a BCMA-targeted antibody-drug conjugate, which was combined with novel checkpoint immuno-oncology monoclonal antibodies and small molecules. Additionally, he has been involved in the design and development of a Phase 3 myeloma trial, integrating an antibody-drug conjugate with an IMiD-based therapy.